The tweet was deleted by the author.
But we saved everything 🙂.
Oric Pharmaceuticals set a date for a conference call and webcast to review clinical data from its ongoing Phase 1b trial of enozertinib in first-line NSCLC patients with EGFR atypical mutations. The stock is up 3.2% on the day at $12.72.
Oric Pharmaceuticals announced a conference call and webcast to review clinical data from its ongoing Phase 1b trial of enozertinib in first-line NSCLC patients with EGFR atypical mutations. The review is scheduled in conjunction with ESMO2026 on Friday, October 23, 2026, at 8:00 a.m. ET. Dr. Joshua Sabari, Assistant Professor of Medicine at NYU Grossman School of Medicine, will join the call to provide his perspective on the enozertinib clinical data, according to GlobeNewswire.
View post on X Loading...
Price reclaimed the MA-20 at $12.56 during the session after closing below it. The daily move remains in line with a broadly bullish chart structure, with shares now positioned above the MA-20 and MA-200 but still below the MA-50, reflecting a split daily structure. The next resistance comes in at the weekly high of $12.86.
To gauge whether the market accepts the latest development, traders should watch the weekly high at $12.86. Earlier in the session, shares moved back above the MA-20 at $12.56 after finishing the previous day underneath that level. Over the next five trading days, there is a 47% probability of upside against a 53% probability of downside, with an expected trading range between $11.99 and $13.44. Even so, after a sharp move higher over the past week without a sustained trend, confirmation would come from a close above $12.86, while rejection would be signaled by a drop below $12.56. On the weekly chart, the longer-term picture stays constructive.
Previously it was reported that Oric Pharmaceuticals maintained a generally bullish technical setup even as shares tested support around the time of a key industry conference. The latest upward move above the MA-20, combined with new clinical data from the enozertinib trial, adds further weight to the constructive longer-term outlook, with the weekly high at $12.86 remaining the critical level to monitor for confirmation of sustained upside.